References
- Ahrén B, Landin-Olsson M, Jansson PA, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 2004;89:2078–2084.
- Utzschneider KM, Tong J, Montgomery B, et al. The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care. 2008;31:108–113.
- Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007;30:890–895.
- Garber AJ, Schweizer A, Baron MA, et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab. 2007;9:166–174.
- Garber AJ, Foley JE, Banerji MA, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab. 2008;10:1047–1056.
- Fonseca V, Baron M, Shao Q, et al. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res. 2008;40:427–430.
- Kikuchi M, Abe N, Kato M, et al. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2009;83:233–240.
- Odawara M, Suzuki M, Hamada I, et al. Clinical evaluation of combination therapy with vildagliptin in patients with type 2 diabetes; safety of add-on to metformin, thiazolidine, α-GI or glinide for 52 weeks (in Japanese). J New Rem Clin. 2012;61:2593–2611.
- Mathieu C, Barnett AH, Brath H, et al. Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE). Int J Clin Pract. 2013;67:947–956.
- Pharmaceuticals and Medical Devices Agency. Vildagliptin (EQUA) package insert. [cited 2018 Oct 2]. Available from: http://www.info.pmda.go.jp/downfiles/ph/PDF/300242_3969011F1020_1_21.pdf [in Japanese].
- Japan Diabetes Clinical Data Management Study Group. 2013. Available from: http://jddm.jp/data/index-2016.html
- Rosales R, Abou Jaoude E, Al-Arouj M, et al. Clinical effectiveness and safety of vildagliptin in >19 000 patients with type 2 diabetes: the GUARD study. Diabetes Obes Metab. 2015;17:603–607.
- Suzuki L, Kanazawa A, Uzawa H, et al. Safety and efficacy of metformin up-titration in Japanese patients with type 2 diabetes mellitus treated with vildagliptin and low-dose metformin. Expert Opin Pharmacother. 2017;18:1921–1928.
- Odawara M, Hamada I, Suzuki M. Efficacy and safety of vildagliptin as add-on to metformin in Japanese patients with type 2 diabetes mellitus. Diabetes Ther. 2014;5:169–181.
- McMurray JJV, Ponikowski P, Bolli GB, et al. Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial. JACC Heart Fail. 2018;6:8–17.
- European Medicines Agency. Galvus (vildagliptin). Summaries of product characteristics. 2012 [cited 2018 Jul 31] Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000771/WC500020327.pdf
- Hirose T, Suzuki M, Tsumiyama I. Efficacy and safety of vildagliptin as an add-on to insulin with or without metformin in Japanese patients with type 2 diabetes mellitus: a 12-week, double-blind, randomized study. Diabetes Ther. 2015;6:559–571.
- Saito D, Kanazawa A, Shiqhara N, et al. Efficacy and safety of vildagliptin as an add-on therapy in inadequately controlled type 2 diabetes patients treated with basal insulin. J Clin Med Res. 2017;9:193–199.
- He YL, Sabo R, Campestrini J, et al. The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers. Br J Clin Pharmacol. 2008;65:338–346.
- Ayvaz G, Keskin L, Akin F, et al. Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey–GALATA study. Curr Med Res Opin. 2015;31:623–632.
- Pratley RE, Rosenstock J, Pi-Sunyer FX, et al. Management of type 2 diabetes in treatment-naive elderly patients. Diabetes Care. 2007;30:3017–3022.
- Umezawa S, Kubota A, Maeda H, et al. Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: post hoc analysis of the ASSET-K study. BMC Endocr Disord. 2015;15:34.
- Kadowaki T, Haneda M, Ito H, et al. Safety and efficacy of long-term treatment with teneligliptin: interim analysis of a post-marketing surveillance of more than 10,000 Japanese patients with type 2 diabetes mellitus. Expert Opin Pharmacother. 2018;19:83–91.